SCHEMBL13753391

SCHEMBL13753391

CC(C)(C)OC(=O)N(CCN)CC(=O)NCCSC(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ KIF11 P52732 18/20 0.43
▸ HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13753316 0.91 KIF11 (0.43) KIF11HPGD
SCHEMBL29455255 0.82 L3MBTL1 (0.37) KIF11HPGD
SCHEMBL12917528 0.81 KIF11 (0.46) KIF11
SCHEMBL9978229 0.80 KIF11 (0.36) KIF11HPGD
SCHEMBL29494628 0.77 SIRT2 (0.40) KIF11
SCHEMBL29494633 0.77 SIRT2 (0.40) KIF11
SCHEMBL12170192 0.76 KIF11 (0.46) KIF11HPGD
SCHEMBL47704 0.76 KIF11 (0.50) KIF11
SCHEMBL19265866 0.76 IDO1 (0.54) KIF11HPGD
SCHEMBL26616743 0.76 ACHE (0.43) KIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250127797-A1 PRODRUG COMPRISING A DRUG-LINKER CONJUGATE ASCENDIS PHARMA A/S (DK) 2025-04-24 — — US disclosed
US-20240041897-A1 PRODRUG COMPRISING A DRUG LINKER CONJUGATE ASCENDIS PHARMA GMBH (DE) 2024-02-08 — — US disclosed
US-20220331334-A1 Prodrug Comprising a Drug-Linker Conjugate ASCENDIS PHARMA A/S (DK) 2022-10-20 — — US disclosed
EP-3981761-A2 INTERMEDIATES FOR PRODRUGS Ascendis Pharma A/S (DK) 2022-04-13 — — EP disclosed
US-20150057221-A1 PRODRUG COMPRISING A DRUG LINKER CONJUGATE ASCENDIS PHARMA AS (DK) 2015-02-26 — — US disclosed
US-8906847-B2 Prodrug comprising a drug linker conjugate ASCENDIS PHARMA A/S (DK) 2014-12-09 — — US disclosed
EP-2596805-A1 Prodrug comprising a drug linker conjugate Ascendis Pharma A/S (DK) 2013-05-29 — — EP disclosed
WO-2009095479-A2 PRODRUG COMPRISING A SELF-CLEAVABLE LINKER ASCENDIS PHARMA AS (DK) 2009-08-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150057221-A1 PRODRUG COMPRISING A DRUG LINKER CONJUGATE H1-0, H1-3, H1-2 KIF11 3253/4885HPGD 1998/4885
US-20240041897-A1 PRODRUG COMPRISING A DRUG LINKER CONJUGATE H1-0, H1-3, H1-2 KIF11 3253/4885HPGD 1998/4885
US-20220331334-A1 Prodrug Comprising a Drug-Linker Conjugate H1-0, H1-3, DLST KIF11 3239/4885HPGD 1728/4885
US-20250127797-A1 PRODRUG COMPRISING A DRUG-LINKER CONJUGATE H1-0, H1-3, DLST KIF11 3239/4885HPGD 1728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback